Literature DB >> 28591541

Lithium Use in Pregnancy and the Risk of Cardiac Malformations.

Elisabetta Patorno1, Krista F Huybrechts1, Brian T Bateman1, Jacqueline M Cohen1, Rishi J Desai1, Helen Mogun1, Lee S Cohen1, Sonia Hernandez-Diaz1.   

Abstract

BACKGROUND: There has been concern that exposure to lithium early in pregnancy may be associated with a marked increase in the risk of Ebstein's anomaly (a right ventricular outflow tract obstruction defect) in infants and overall congenital cardiac defects, but data are conflicting and limited.
METHODS: We conducted a cohort study involving 1,325,563 pregnancies in women who were enrolled in Medicaid and who delivered a live-born infant between 2000 and 2010. We examined the risk of cardiac malformations among infants exposed to lithium during the first trimester as compared with unexposed infants and, in secondary analyses, with infants exposed to another commonly used mood stabilizer, lamotrigine. Risk ratios and 95% confidence intervals were estimated with control for psychiatric and medical conditions, medications, and other potential confounders.
RESULTS: Cardiac malformations were present in 16 of the 663 infants exposed to lithium (2.41%), 15,251 of the 1,322,955 nonexposed infants (1.15%), and 27 of the 1945 infants exposed to lamotrigine (1.39%). The adjusted risk ratio for cardiac malformations among infants exposed to lithium as compared with unexposed infants was 1.65 (95% confidence interval [CI], 1.02 to 2.68). The risk ratio was 1.11 (95% CI, 0.46 to 2.64) for a daily dose of 600 mg or less, 1.60 (95% CI, 0.67 to 3.80) for 601 to 900 mg, and 3.22 (95% CI, 1.47 to 7.02) for more than 900 mg. The prevalence of right ventricular outflow tract obstruction defects was 0.60% among lithium-exposed infants versus 0.18% among unexposed infants (adjusted risk ratio, 2.66; 95% CI, 1.00 to 7.06). Results were similar when lamotrigine-exposed infants were used as the reference group.
CONCLUSIONS: Maternal use of lithium during the first trimester was associated with an increased risk of cardiac malformations, including Ebstein's anomaly; the magnitude of this effect was smaller than had been previously postulated. (Funded by the National Institute of Mental Health.).

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28591541      PMCID: PMC5667676          DOI: 10.1056/NEJMoa1612222

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  33 in total

1.  A case-control study on the association between first trimester exposure to lithium and Ebstein's anomaly.

Authors:  E Zalzstein; G Koren; T Einarson; R M Freedom
Journal:  Am J Cardiol       Date:  1990-03-15       Impact factor: 2.778

2.  Teratogenic effect of lithium carbonate in the foetal mouse.

Authors:  K T Szabo
Journal:  Nature       Date:  1970-01-03       Impact factor: 49.962

3.  Prenatal echocardiographic screening for Ebstein's anomaly for mothers on lithium therapy.

Authors:  L D Allan; G Desai; M J Tynan
Journal:  Lancet       Date:  1982-10-16       Impact factor: 79.321

4.  Letter: Lithium, Ebstein's anomaly, and other congenital heart defects.

Authors:  J J Nora; A H Nora; W H Toews
Journal:  Lancet       Date:  1974-09-07       Impact factor: 79.321

Review 5.  Valproic acid monotherapy in pregnancy and major congenital malformations.

Authors:  Janneke Jentink; Maria A Loane; Helen Dolk; Ingeborg Barisic; Ester Garne; Joan K Morris; Lolkje T W de Jong-van den Berg
Journal:  N Engl J Med       Date:  2010-06-10       Impact factor: 91.245

6.  Evaluation of drug intake during pregnancy in the Hungarian Case-Control Surveillance of Congenital Anomalies.

Authors:  A Czeizel; J Rácz
Journal:  Teratology       Date:  1990-11

7.  Cardiovascular malformations with lithium use during pregnancy.

Authors:  M R Weinstein; M Goldfield
Journal:  Am J Psychiatry       Date:  1975-05       Impact factor: 18.112

Review 8.  Is lithium a real teratogen? What can we conclude from the prospective versus retrospective studies? A review.

Authors:  Sarah Yacobi; Asher Ornoy
Journal:  Isr J Psychiatry Relat Sci       Date:  2008       Impact factor: 0.481

9.  Teratogenic effects of lithium in mice.

Authors:  M Smithberg; P K Dixit
Journal:  Teratology       Date:  1982-12

10.  Lithium and pregnancy. A cohort study on manic-depressive women.

Authors:  B Källén; A Tandberg
Journal:  Acta Psychiatr Scand       Date:  1983-08       Impact factor: 6.392

View more
  41 in total

1.  Maternal and infant outcomes associated with lithium use in pregnancy: an international collaborative meta-analysis of six cohort studies.

Authors:  Trine Munk-Olsen; Xiaoqin Liu; Alexander Viktorin; Hilary K Brown; Arianna Di Florio; Brian M D'Onofrio; Tara Gomes; Louise M Howard; Hind Khalifeh; Holly Krohn; Henrik Larsson; Paul Lichtenstein; Clare L Taylor; Inge Van Kamp; Richard Wesseloo; Samantha Meltzer-Brody; Simone N Vigod; Veerle Bergink
Journal:  Lancet Psychiatry       Date:  2018-06-18       Impact factor: 27.083

Review 2.  Lithium Use and Non-use for Pregnant and Postpartum Women with Bipolar Disorder.

Authors:  Alison Hermann; Alyson Gorun; Abigail Benudis
Journal:  Curr Psychiatry Rep       Date:  2019-11-07       Impact factor: 5.285

Review 3.  Recognizing and Managing Postpartum Psychosis: A Clinical Guide for Obstetric Providers.

Authors:  Lauren M Osborne
Journal:  Obstet Gynecol Clin North Am       Date:  2018-09       Impact factor: 2.844

4.  Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder.

Authors:  Lakshmi N Yatham; Sidney H Kennedy; Sagar V Parikh; Ayal Schaffer; David J Bond; Benicio N Frey; Verinder Sharma; Benjamin I Goldstein; Soham Rej; Serge Beaulieu; Martin Alda; Glenda MacQueen; Roumen V Milev; Arun Ravindran; Claire O'Donovan; Diane McIntosh; Raymond W Lam; Gustavo Vazquez; Flavio Kapczinski; Roger S McIntyre; Jan Kozicky; Shigenobu Kanba; Beny Lafer; Trisha Suppes; Joseph R Calabrese; Eduard Vieta; Gin Malhi; Robert M Post; Michael Berk
Journal:  Bipolar Disord       Date:  2018-03-14       Impact factor: 6.744

Review 5.  Use of real-world evidence from healthcare utilization data to evaluate drug safety during pregnancy.

Authors:  Krista F Huybrechts; Brian T Bateman; Sonia Hernández-Díaz
Journal:  Pharmacoepidemiol Drug Saf       Date:  2019-05-10       Impact factor: 2.890

Review 6.  Psychotropic Treatment During Pregnancy: Research Synthesis and Clinical Care Principles.

Authors:  Hannah K Betcher; Katherine L Wisner
Journal:  J Womens Health (Larchmt)       Date:  2019-12-03       Impact factor: 2.681

Review 7.  Dose-Dependent Teratology in Humans: Clinical Implications for Prevention.

Authors:  Gideon Koren; Matitiahu Berkovitch; Asher Ornoy
Journal:  Paediatr Drugs       Date:  2018-08       Impact factor: 3.022

8.  Neonatal Outcomes in a Medicaid Population With Opioid Dependence.

Authors:  Susan B Brogly; Sonia Hernández-Diaz; Emily Regan; Ela Fadli; Kristen A Hahn; Martha M Werler
Journal:  Am J Epidemiol       Date:  2018-06-01       Impact factor: 4.897

Review 9.  Psychopharmacological Decision Making in Bipolar Disorder During Pregnancy and Lactation: A Case-by-Case Approach to Using Current Evidence.

Authors:  Elizabeth Albertini; Carrie L Ernst; Rachel S Tamaroff
Journal:  Focus (Am Psychiatr Publ)       Date:  2019-07-16

10. 

Authors:  Sinéad M Langan; Sigrún A J Schmidt; Kevin Wing; Vera Ehrenstein; Stuart G Nicholls; Kristian B Filion; Olaf Klungel; Irene Petersen; Henrik T Sørensen; William G Dixon; Astrid Guttmann; Katie Harron; Lars G Hemkens; David Moher; Sebastian Schneeweiss; Liam Smeeth; Miriam Sturkenboom; Erik von Elm; Shirley V Wang; Eric I Benchimol
Journal:  CMAJ       Date:  2019-06-24       Impact factor: 8.262

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.